Literature DB >> 25795775

A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis.

Rozita Bagheri-Yarmand1, Krishna M Sinha2, Anupama E Gururaj3, Zamal Ahmed4, Yasmeen Q Rizvi2, Su-Chen Huang2, John E Ladbury4, Oliver Bogler3, Michelle D Williams5, Gilbert J Cote2, Robert F Gagel2.   

Abstract

The RET proto-oncogene, a tyrosine kinase receptor, is widely known for its essential role in cell survival. Germ line missense mutations, which give rise to constitutively active oncogenic RET, were found to cause multiple endocrine neoplasia type 2, a dominant inherited cancer syndrome that affects neuroendocrine organs. However, the mechanisms by which RET promotes cell survival and prevents cell death remain elusive. We demonstrate that in addition to cytoplasmic localization, RET is localized in the nucleus and functions as a tyrosine-threonine dual specificity kinase. Knockdown of RET by shRNA in medullary thyroid cancer-derived cells stimulated expression of activating transcription factor 4 (ATF4), a master transcription factor for stress-induced apoptosis, through activation of its target proapoptotic genes NOXA and PUMA. RET knockdown also increased sensitivity to cisplatin-induced apoptosis. We observed that RET physically interacted with and phosphorylated ATF4 at tyrosine and threonine residues. Indeed, RET kinase activity was required to inhibit the ATF4-dependent activation of the NOXA gene because the site-specific substitution mutations that block threonine phosphorylation increased ATF4 stability and activated its targets NOXA and PUMA. Moreover, chromatin immunoprecipitation assays revealed that ATF4 occupancy increased at the NOXA promoter in TT cells treated with tyrosine kinase inhibitors or the ATF4 inducer eeyarestatin as well as in RET-depleted TT cells. Together these findings reveal RET as a novel dual kinase with nuclear localization and provide mechanisms by which RET represses the proapoptotic genes through direct interaction with and phosphorylation-dependent inactivation of ATF4 during the pathogenesis of medullary thyroid cancer.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Apoptosis; Thyroid; Transcription Regulation; Transcription Repressor; Tyrosine-Protein Kinase (Tyrosine Kinase); Ubiquitylation (Ubiquitination)

Mesh:

Substances:

Year:  2015        PMID: 25795775      PMCID: PMC4416875          DOI: 10.1074/jbc.M114.619833

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA.

Authors:  Zohreh Galehdar; Patrick Swan; Benjamin Fuerth; Steven M Callaghan; David S Park; Sean P Cregan
Journal:  J Neurosci       Date:  2010-12-15       Impact factor: 6.167

2.  cAMP-response element (CRE)-mediated transcription by activating transcription factor-4 (ATF4) is essential for circadian expression of the Period2 gene.

Authors:  Satoru Koyanagi; Ahmed M Hamdan; Michiko Horiguchi; Naoki Kusunose; Akinori Okamoto; Naoya Matsunaga; Shigehiro Ohdo
Journal:  J Biol Chem       Date:  2011-07-18       Impact factor: 5.157

3.  Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways.

Authors:  L Zhang; H Lopez; N M George; X Liu; X Pang; X Luo
Journal:  Cell Death Differ       Date:  2010-11-26       Impact factor: 15.828

4.  An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs.

Authors:  C Sheridan; G Brumatti; M Elgendy; M Brunet; S J Martin
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

5.  The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.

Authors:  Qiuyan Wang; Bidhan A Shinkre; Jin-gu Lee; Marc A Weniger; Yanfen Liu; Weiping Chen; Adrian Wiestner; William C Trenkle; Yihong Ye
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

6.  Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

Authors:  Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

7.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

8.  KIF5B-RET fusions in lung adenocarcinoma.

Authors:  Takashi Kohno; Hitoshi Ichikawa; Yasushi Totoki; Kazuki Yasuda; Masaki Hiramoto; Takao Nammo; Hiromi Sakamoto; Koji Tsuta; Koh Furuta; Yoko Shimada; Reika Iwakawa; Hideaki Ogiwara; Takahiro Oike; Masato Enari; Aaron J Schetter; Hirokazu Okayama; Aage Haugen; Vidar Skaug; Suenori Chiku; Itaru Yamanaka; Yasuhito Arai; Shun-Ichi Watanabe; Ikuo Sekine; Seishi Ogawa; Curtis C Harris; Hitoshi Tsuda; Teruhiko Yoshida; Jun Yokota; Tatsuhiro Shibata
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

9.  Control of activating transcription factor 4 (ATF4) persistence by multisite phosphorylation impacts cell cycle progression and neurogenesis.

Authors:  Christopher L Frank; Xuecai Ge; Zhigang Xie; Ying Zhou; Li-Huei Tsai
Journal:  J Biol Chem       Date:  2010-08-19       Impact factor: 5.157

10.  FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal.

Authors:  Han You; Marc Pellegrini; Katsuya Tsuchihara; Kazuo Yamamoto; Georg Hacker; Miriam Erlacher; Andreas Villunger; Tak W Mak
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307

View more
  20 in total

1.  Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer.

Authors:  Rozita Bagheri-Yarmand; Krishna M Sinha; Ling Li; Yue Lu; Gilbert J Cote; Steven I Sherman; Robert F Gagel
Journal:  Mol Cancer Res       Date:  2018-12-14       Impact factor: 5.852

Review 2.  The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors:  Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

Review 3.  Surviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells.

Authors:  Inge M N Wortel; Laurens T van der Meer; Michael S Kilberg; Frank N van Leeuwen
Journal:  Trends Endocrinol Metab       Date:  2017-08-07       Impact factor: 12.015

Review 4.  Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Authors:  Jacob J Adashek; Aakash P Desai; Alexander Y Andreev-Drakhlin; Jason Roszik; Gilbert J Cote; Vivek Subbiah
Journal:  Mol Cancer Ther       Date:  2021-09-06       Impact factor: 6.261

5.  ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.

Authors:  Rozita Bagheri-Yarmand; Michelle D Williams; Elizabeth G Grubbs; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

6.  ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.

Authors:  Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 7.  Biology of Activating Transcription Factor 4 (ATF4) and Its Role in Skeletal Muscle Atrophy.

Authors:  Scott M Ebert; Blake B Rasmussen; Andrew R Judge; Sarah M Judge; Lars Larsson; Ronald C Wek; Tracy G Anthony; George R Marcotte; Matthew J Miller; Mark A Yorek; Adrian Vella; Elena Volpi; Jennifer I Stern; Matthew D Strub; Zachary Ryan; John J Talley; Christopher M Adams
Journal:  J Nutr       Date:  2022-04-01       Impact factor: 4.798

8.  ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2.

Authors:  Rozita Bagheri-Yarmand; Ramona Dadu; Lei Ye; Yaashmin Shiny Jebaraj; Jade A Martinez; Junsheng Ma; Rohinton S Tarapore; Joshua E Allen; Steven I Sherman; Michelle D Williams; Robert F Gagel
Journal:  Mol Cancer Ther       Date:  2021-02-03       Impact factor: 6.009

9.  RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements.

Authors:  Iván Plaza-Menacho; Karin Barnouin; Rachael Barry; Annabel Borg; Mariam Orme; Rakhee Chauhan; Stephane Mouilleron; Rubén J Martínez-Torres; Pascal Meier; Neil Q McDonald
Journal:  Cell Rep       Date:  2016-12-20       Impact factor: 9.423

10.  HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Authors:  Setareh Safavi; Sofia Järnum; Christoffer Vannas; Sameer Udhane; Emma Jonasson; Tajana Tesan Tomic; Pernilla Grundevik; Henrik Fagman; Magnus Hansson; Zeynep Kalender; Alexandra Jauhiainen; Soheila Dolatabadi; Eva Wessel Stratford; Ola Myklebost; Mikael Eriksson; Göran Stenman; Regine Schneider-Stock; Anders Ståhlberg; Pierre Åman
Journal:  Oncotarget       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.